ArticleMolecular therapy. Oncology2026
USP15 regulates mitotic fidelity, metastatic potential, and chemotherapeutic response in ovarian cancer cells.
Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Aggressive metastasis and chemoresistance are underlying cause for the poor clinical outcome in ovarian cancer patients. Identifying factors that drive these phenotypes is critical in developing effective therapeutic strategies for metastatic ovarian cancer. In this report, we show that the deubiquitinase USP15 is a critical regulator of ovarian cancer cell proliferation, metastasis, and drug resistance. USP15 levels are elevated in metastatic ovarian tumors and are associated with poor clinical outcome in patients. Depletion and inhibition of USP15 dramatically reduces cell viability and proliferation in a broad spectrum of ovarian cancer cells. Mechanistically, USP15 knockdown disrupts chromosomal segregation, leading to DNA damage, micronuclei formation, and mitotic catastrophe. This causes ovarian cancer cells to undergo cell-cycle arrest at the G2-M checkpoint. Further, USP15 knockdown decreases the metastatic potential of ovarian cancer cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.